InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy

InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext specializing in biological research reagents and related technical contract research services, today announced a new partnership to speed development of multiplexed assays for a broad range of vaccine, mRNA therapies and cell and gene therapy applications.

Through this partnership, Sino Biological’s catalog of high-quality antibodies, antigens, and other reagents are available for use on InDevR’s VaxArray Platform. Biopharmaceutical companies worldwide currently employ the VaxArray Platform’s multiplex assay capabilities in their vaccine testing to simplify, standardize and speed novel vaccine development, optimization of existing formulations and production scale-up.The two companies aim to accelerate the development and deployment of multiparametric analytical tools to aid researchers in driving advancements in mRNA, vaccine development and the rapidly evolving field of cell and gene therapy.

Since 2003, InDevR’s core focus has been to deliver innovative analytical tools for the vaccine industry.

Moving forward, our goal is to leverage that expertise to address the urgent need for improved analytical tools for cell and gene therapies and mRNA vaccine testing. Our partnership with Sino Biological, with their extraordinary breadth and depth of offerings and commitment to quality, will drive new product development and empower our customers to design their own multiplex assays with ease,”

Dr. Kathy Rowlen, CEO, InDevR

Experts in recombinant protein production and antibody development, Sino Biological is equally enthusiastic about the collaboration. "We are thrilled to partner with InDevR to enhance the capabilities of their VaxArray Platform," Sino Biological Chief Business Officer Dr. Rob Burgess stated. "Our comprehensive range of quality reagents, combined with InDevR's cutting-edge analytical technology, promises to deliver superior solutions for in-process and quality control testing in the biopharmaceutical industry."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2024, June 07). InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy. News-Medical. Retrieved on July 22, 2024 from https://www.news-medical.net/news/20240607/InDevR-and-Sino-Biological-team-up-to-deliver-multiplexed-analytical-solutions-for-mRNA-vaccine-and-cell-gene-therapy.aspx.

  • MLA

    Sino Biological Inc.. "InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy". News-Medical. 22 July 2024. <https://www.news-medical.net/news/20240607/InDevR-and-Sino-Biological-team-up-to-deliver-multiplexed-analytical-solutions-for-mRNA-vaccine-and-cell-gene-therapy.aspx>.

  • Chicago

    Sino Biological Inc.. "InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy". News-Medical. https://www.news-medical.net/news/20240607/InDevR-and-Sino-Biological-team-up-to-deliver-multiplexed-analytical-solutions-for-mRNA-vaccine-and-cell-gene-therapy.aspx. (accessed July 22, 2024).

  • Harvard

    Sino Biological Inc.. 2024. InDevR and Sino Biological team up to deliver multiplexed analytical solutions for mRNA vaccine and cell & gene therapy. News-Medical, viewed 22 July 2024, https://www.news-medical.net/news/20240607/InDevR-and-Sino-Biological-team-up-to-deliver-multiplexed-analytical-solutions-for-mRNA-vaccine-and-cell-gene-therapy.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Therapeutic potential of CD20 x CD3 bispecific antibodies